Skip to content

Chitosan supplementation and Coronavirus

The effect of chitosan supplementation on clinical symptoms in patients with COVID-19

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210510051243N1
Enrollment
80
Registered
2021-05-25
Start date
2021-05-31
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection. COVID-19

Interventions

Intervention 1: Intervention group: receive 10 cc of the same 2.5% chitosan syrup (250?mg pharmacological grade chitosan) during the day, for 2 weeks.All syrups are prepared by the Barij Essence Phar

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age between 20 to 75 years, Willingness to participate with written informed consent, Diagnosis of coronavirus based on the PCR test.

Exclusion criteria

Exclusion criteria: Current use of warfarin, Presence of sensitivity to seafood.

Design outcomes

Primary

MeasureTime frame
Respiratory Rate. Timepoint: day 1 and day 14. Method of measurement: The number of breaths a person takes per minute.;Severity of lung involvement. Timepoint: day 1 and day 14. Method of measurement: Chest CT scan.;High-sensitivity C-reactive protein. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Erythrocyte Sedimentation Rate. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Severity and number of coughs. Timepoint: Day 1 and day 14. Method of measurement: Cough visual analogue scale (VAS).;Body temperature. Timepoint: Day 1 and day 14. Method of measurement: Clinical Thermometer.;Alanine aminotransferase Activity. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Aspartate aminotransferase Activity. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Superoxide dismutase Activity. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Albumin. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Death outcome. Timepoint: Day 14. Method of measurement: Percentage of fatal patients in two groups.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Abtahi

Arak University of Medical Sciences

abtahi@arakmu.ac.ir+98 86 3417 3502

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026